The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site

K Befort, L Tabbara, S Bausch, C Chavkin, C Evans and B Kieffer

Ecole Superieure de Biotechnologie, Parc d'Innovation, Illkirch- Graffenstaden, France.

Opioids are cationic compounds that mediate their biological action through three highly homologous receptors (mu, delta, and kappa) known to belong to the G protein-coupled receptor (GPR) family. The third putative transmembrane domain of opioid receptors contains a conserved aspartate residue that is typically found in biogenic amine binding GPRs and is generally believed to form an ion pair with the cationic neurotransmitters. Using site-directed mutagenesis, we investigated the possibility of an identical role for this residue (Asp128) in the mouse delta-opioid receptor. Removal of the carboxylate group via an aspartate-to-alanine mutation did not modify binding affinity of a representative set of opioid compounds, including bremazocine, diprenorphine, naloxone, Tyr-D-Thr-Gly-Phe-Leu-Thr, [D-Ala2,D- Leu5]enkephalin, cyclic[D-penicillamine2,D-penicillamine5]enkephalin, deltorphin II, (+/-)-4-[(a-R*)-a-[(2S*,5R*)-4-allyl-2,5-di-methyl-1- piperazinyl]-3-hydroxybenzyl]-N,N-diethylbenzamide, and naltrindole. It nevertheless decreased receptor expression level and affected the binding of three agonists ([D-Ala2,D-Leu5]enkephalin, Tyr-D-Thr-Gly-Phe- Leu-Thr, and (+/-)-4-[(a-R*)-a-[(2S*,5R*)-4-allyl-2,5-di- methyl-1- piperazinyl]-3-hydroxybenzyl]-N,N-diethylbenzamide) when the receptor was under Na(+)-induced low affinity state. On the other hand, the aspartate-to-asparagine mutation strongly impaired the binding of all of the above ligands and highlighted differential modes of interaction for alkaloids and peptides. Finally, removal of the homologous carboxylate group in the mouse mu receptor had distinct effects because it dramatically reduced the binding potency of some, but not all, tested ligands. Taken together, these results demonstrate that (i) the direct ligand/receptor interaction previously demonstrated for the beta- adrenergic receptor does not take place in the delta receptor, (ii) Asp128 nevertheless contributes to stabilization of the spatial conformation of the binding pocket, and (iii) these conclusions cannot be extended to the closely related mu receptor.

Volume 49, Issue 2, pp. 216-223, 02/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				V. Gonzalez-Nunez, G. Arsequell, E. Szemenyei, G. Toth, G. Valencia, and R. E. Rodriguez Binding Profile of the Endogenous Novel Heptapeptide Met-Enkephalin-Gly-Tyr in Zebrafish and Rat Brain J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 862 - 867. [Abstract] [Full Text] [PDF]

				M. Aburi and P. E. Smith Modeling and simulation of the human {delta} opioid receptor Protein Sci., August 1, 2004; 13(8): 1997 - 2008. [Abstract] [Full Text] [PDF]

				I. Fadhil, R. Schmidt, C. Walpole, and K. A. Carpenter Exploring Deltorphin II Binding to the Third Extracellular Loop of the {delta}-Opioid Receptor J. Biol. Chem., May 14, 2004; 279(20): 21069 - 21077. [Abstract] [Full Text] [PDF]

				J. P. McLaughlin, M. Xu, K. Mackie, and C. Chavkin Phosphorylation of a Carboxyl-terminal Serine within the {kappa}-Opioid Receptor Produces Desensitization and Internalization J. Biol. Chem., September 5, 2003; 278(36): 34631 - 34640. [Abstract] [Full Text] [PDF]

				C. Chavkin, J. P. McLaughlin, and J. P. Celver Regulation of Opioid Receptor Function by Chronic Agonist Exposure: Constitutive Activity and Desensitization Mol. Pharmacol., July 1, 2001; 60(1): 20 - 25. [Full Text]

				J. P. McLaughlin and C. Chavkin Tyrosine Phosphorylation of the {micro}-Opioid Receptor Regulates Agonist Intrinsic Efficacy Mol. Pharmacol., June 1, 2001; 59(6): 1360 - 1368. [Abstract] [Full Text]

				C. M. Topham, L. Mouledous, and J.-C. Meunier On the spatial disposition of the fifth transmembrane helix and the structural integrity of the transmembrane binding site in the opioid and ORL1 G protein-coupled receptor family Protein Eng. Des. Sel., July 1, 2000; 13(7): 477 - 490. [Abstract] [Full Text] [PDF]

				L. Mouledous, C. M. Topham, C. Moisand, C. Mollereau, and J.-C. Meunier Functional Inactivation of the Nociceptin Receptor by Alanine Substitution of Glutamine 286 at the C Terminus of Transmembrane Segment VI: Evidence from a Site-Directed Mutagenesis Study of the ORL1 Receptor Transmembrane-Binding Domain Mol. Pharmacol., March 1, 2000; 57(3): 495 - 502. [Abstract] [Full Text]

				M. Filizola, L. Laakkonen, and G. H. loew 3D modeling, ligand binding and activation studies of the cloned mouse {delta}, {micro} and {kappa} opioid receptors Protein Eng. Des. Sel., November 1, 1999; 12(11): 927 - 942. [Abstract] [Full Text] [PDF]

				P. Sánchez-Blázquez, M. Rodríguez-Díaz, I. DeAntonio, and J. Garzón Endomorphin-1 and Endomorphin-2 Show Differences in Their Activation of {micro} Opioid Receptor-Regulated G Proteins in Supraspinal Antinociception in Mice J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 12 - 18. [Abstract] [Full Text]

				R. M. Quock, T. H. Burkey, E. Varga, Y. Hosohata, K. Hosohata, S. M. Cowell, C. A. Slate, F. J. Ehlert, W. R. Roeske, and H. I. Yamamura The delta -Opioid Receptor: Molecular Pharmacology, Signal Transduction, and the Determination of Drug Efficacy Pharmacol. Rev., September 1, 1999; 51(3): 503 - 532. [Abstract] [Full Text] [PDF]

				K. Befort, C. Zilliox, D. Filliol, S. Yue, and B. L. Kieffer Constitutive Activation of the delta  Opioid Receptor by Mutations in Transmembrane Domains III and VII J. Biol. Chem., June 25, 1999; 274(26): 18574 - 18581. [Abstract] [Full Text] [PDF]

				A. Marjamäki, M. Pihlavisto, V. Cockcroft, P. Heinonen, J.-M. Savola, and M. Scheinin Chloroethylclonidine Binds Irreversibly to Exposed Cysteines in the Fifth Membrane-Spanning Domain of the Human alpha 2A-Adrenergic Receptor Mol. Pharmacol., March 1, 1998; 53(3): 370 - 376. [Abstract] [Full Text]

				G. Bot, A. D. Blake, S. Li, and T. Reisine Mutagenesis of the Mouse Delta Opioid Receptor Converts (-)-Buprenorphine from a Partial Agonist to an Antagonist J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 283 - 290. [Abstract] [Full Text]

				A. Kovoor, V. Nappey, B. L. Kieffer, and C. Chavkin µ and delta  Opioid Receptors Are Differentially Desensitized by the Coexpression of beta -Adrenergic Receptor Kinase 2 and beta -Arrestin 2 in Xenopus Oocytes J. Biol. Chem., October 31, 1997; 272(44): 27605 - 27611. [Abstract] [Full Text] [PDF]

				D. Massotte, L. Baroche, F. Simonin, L. Yu, B. Kieffer, and F. Pattus Characterization of delta , kappa , and µ Human Opioid Receptors Overexpressed in Baculovirus-infected Insect Cells J. Biol. Chem., August 8, 1997; 272(32): 19987 - 19992. [Abstract] [Full Text] [PDF]

				G. Bot, A. D. Blake, S. Li, and T. Reisine Opioid Regulation of the Mouse delta -Opioid Receptor Expressed in Human Embryonic Kidney 293 Cells Mol. Pharmacol., August 1, 1997; 52(2): 272 - 281. [Abstract] [Full Text]

				G. Gaudriault, D. Nouel, C. Dal Farra, A. Beaudet, and J.-P. Vincent Receptor-induced Internalization of Selective Peptidicµand delta Opioid Ligands J. Biol. Chem., January 31, 1997; 272(5): 2880 - 2888. [Abstract] [Full Text] [PDF]

				C. Chen, J. Yin, J. K. d. Riel, R. L. DesJarlais, L. F. Raveglia, J. Zhu, and L.-Y. Liu-Chen Determination of the Amino Acid Residue Involved in [3H]beta -Funaltrexamine Covalent Binding in the Cloned RatµOpioid Receptor J. Biol. Chem., August 30, 1996; 271(35): 21422 - 21429. [Abstract] [Full Text] [PDF]

				K. Befort, L. Tabbara, D. Kling, B. Maigret, and B. L. Kieffer Role of Aromatic Transmembrane Residues of the [IMAGE]-Opioid Receptor in Ligand Recognition J. Biol. Chem., April 26, 1996; 271(17): 10161 - 10168. [Abstract] [Full Text] [PDF]

				K. Befort, D. Filliol, F. M. Decaillot, C. Gaveriaux-Ruff, M. R. Hoehe, and B. L. Kieffer A Single Nucleotide Polymorphic Mutation in the Human {micro}-Opioid Receptor Severely Impairs Receptor Signaling J. Biol. Chem., January 26, 2001; 276(5): 3130 - 3137. [Abstract] [Full Text] [PDF]